Dirk Kersten Sells Shares of Dyne Therapeutics
On June 18, Dirk Kersten sold 46,901 shares of Dyne Therapeutics, Inc., totaling $941,303.07.
Key Points
- Dirk Kersten sold 46,901 shares of Dyne Therapeutics, Inc. on June 18, 2026, at an average price of $20.07 per share.
- Dyne Therapeutics, Inc. trades on NasdaqGS under the ticker DYN with a market cap of $3.27 billion and a 52-week high of $25.00.
- Analysts maintain a strong buy consensus for Dyne Therapeutics, Inc., with a target mean price of $38.25.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Dirk Kersten, an insider at Dyne Therapeutics, Inc. (NasdaqGS: DYN), sold 46,901 shares on June 18, 2026. The shares were sold at an average price of $20.07, totaling $941,303.07. This transaction was planned under a Rule 10b5-1 trading plan.
Insider Buying and Selling at Dyne Therapeutics, Inc.
In addition to Dirk Kersten's recent sale, other insiders at Dyne Therapeutics have been active. On June 17, Kersten sold another 37,454 shares at $20.14 each. Earlier, on June 16, several executives including Chief Medical Officer Douglas Kerr and CEO John Cox sold shares at $18.33 per share. Brian Posner, however, bought 2,000 shares at $16.94 on June 8, not under a trading plan.
Other Institutional Activity in Dyne Therapeutics
Institutional investors have also been making moves with Dyne Therapeutics. T. Rowe Price Investment Management, Inc. increased its holdings by 13,245,712 shares, ending with 30,785,801 shares valued at about $558.15 million. Meanwhile, Janus Henderson Group PLC slightly reduced its stake by 240,346 shares, holding 13,647,376 shares worth approximately $247.43 million. BlackRock, Inc. added 509,032 shares, bringing its total to 11,699,870 shares valued at $212.12 million. FMR LLC boosted its holdings by 2,339,059 shares, reaching 8,908,980 shares worth $161.52 million. Orbis Allan Gray Ltd also increased its position by 1,960,303 shares, holding a total of 6,762,231 shares valued at $122.60 million.
Dyne Therapeutics, Inc. Stock Down 16.8%
As of Tuesday, shares of Dyne Therapeutics, Inc. (NasdaqGS: DYN) traded near $20.87. The company has a market capitalization of approximately $3.27 billion. Dyne Therapeutics is not profitable, which means it does not have a meaningful P/E ratio. The stock has a 52-week range of $8.06 to $25.00, with a 50-day moving average of $18.29 and a 200-day moving average of $17.67. The company maintains a strong liquidity position with a current ratio of 19.92 and a quick ratio of 18.97.
$DYN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analysts are optimistic about Dyne Therapeutics. On May 15, 2026, Evercore ISI Group maintained a 'buy' rating with a $33.00 price target. Other firms like HC Wainwright & Co. and Morgan Stanley have also kept 'buy' ratings, with targets of $50.00 and $47.00 respectively. Overall, the consensus recommendation is a 'strong buy' with a mean target price of $38.25, based on 16 analyst opinions.
About Dyne Therapeutics
Dyne Therapeutics, Inc., headquartered in Waltham, Massachusetts, is a biotechnology company focused on developing treatments for neuromuscular diseases. Its pipeline includes therapies for conditions like myotonic dystrophy type 1 and Duchenne muscular dystrophy. The company uses its FORCE platform to deliver disease-modifying therapeutics. Led by CEO John G. Cox, Dyne employs 263 people and was founded in 2017.
Bottom Line
Dirk Kersten's sale of shares in Dyne Therapeutics is part of a planned transaction, reflecting ongoing insider activity. The company's stock shows strong institutional interest and a positive analyst outlook. Investors keep an eye on these developments as part of their broader strategy, but remember that insider transactions and analyst ratings are just pieces of the investing puzzle.
Get Dyne Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $DYN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.